Tirzepatide (Mounjaro®) for Weight Management – NHS Access Update
We understand that many patients are interested in tirzepatide (Mounjaro®) for weight loss. NHS England and Lincolnshire ICB has announced a phased rollout of this new treatment, and we’d like to share the latest information about how it will be made available in primary care.
Initially, tirzepatide will only be offered to patients with the highest clinical need. Specifically, this includes individuals living with obesity who meet all of the following criteria:
Have a BMI of 40 or more (adjusted for ethnicity).
Have been diagnosed with four or more weight-related health conditions, such as high blood pressure, type 2 diabetes, or sleep apnoea.
Eligible patients will not need to apply or make a request to their GP. Instead, they will be contacted directly and offered the treatment if they meet the criteria. As part of the programme, patients will also receive wraparound care, which includes support with diet and physical activity to ensure the best outcomes.
In the Lincolnshire ICB area, it is expected that only a small cohort of patients may be eligible in the first year.
We appreciate your understanding as this service is gradually introduced to support those with the greatest health need.
Useful Websites
Weight Loss Injections & Contraception Risks
Please see the attached guide regarding the risks of weight loss injections and contraception – Patient-information-GLP-1-agonists-and-contraception